Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]

Core Viewpoint - The lithium battery sector has shown significant strength, with multiple stocks reaching their daily limit up, indicating a bullish trend in the market [1]. Group 1: Stock Performance - Stocks such as Fengyuan Co., Tianci Materials, Yongshan Lithium, and Shengxin Lithium Energy have hit the daily limit up, reflecting strong investor interest [1]. - Nearly 30 stocks in the sector have seen price increases of 10% or more, showcasing a broad rally in the lithium battery industry [1]. Group 2: Notable Stock Gains - An Da Technology increased by 20.91%, with a market value of 6.14 billion [2]. - Rui Tai New Materials rose by 20.00%, with a market value of 14.80 billion [2]. - Qing Shui Yuan saw a gain of 19.97%, with a market value of 7.55 billion [2]. - Wanrun New Energy increased by 19.43%, with a market value of 13.66 billion [2]. - Huasheng Lithium Battery rose by 16.94%, with a market value of 11.75 billion [2]. - Other notable gains include Fu Xiang Pharmaceutical (+15.78%), Defang Nano (+13.58%), and Hai Ke New Source (+13.00%) [2].

Core Viewpoint - Huaxi Biological is facing a trust crisis in the capital market due to continuous shareholding reduction by original shareholders and a significant drop in stock price, which has fallen over 80% from its peak. The company's core skincare business has seen a substantial decline in revenue over the past two years, leading to a notable decrease in both revenue and net profit for the first three quarters of 2025. The company is undergoing a "bone-scraping" reform to improve profitability through cost reduction and efficiency enhancement, while also seeking new growth through external investments. However, the lack of internal growth drivers and the underperformance of core business pose significant challenges for the company's recovery and investment transformation [2][3][4]. Financial Performance - As of November 6, 2025, Huaxi Biological's stock price was 49.8 yuan per share, representing an over 82% decline from its historical peak, with a market capitalization of only 24 billion yuan, down more than 120 billion yuan from its peak [4]. - For the first three quarters of 2025, the company reported revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% compared to the previous year [4][5]. - The core skincare innovation business has seen a continuous decline in revenue, with a drop of 8.5 billion yuan in 2023 and a further decline to 2.569 billion yuan in 2025, reflecting a year-on-year decrease of over 30% [5][6]. Business Challenges - The raw materials and medical terminal segments have also experienced declines, with the raw materials business showing a slight decrease of 0.58% in the first half of 2025, and the medical terminal business declining by 9.44% [6]. - The company's cost control measures have led to a reduction in sales expenses, which decreased by 5.14 billion yuan to 1.117 billion yuan in the first three quarters of 2025, resulting in a sales expense ratio of 34.26%, down 31.50% [9][10]. Strategic Initiatives - The company has initiated a brand "slimming" plan, shutting down non-core brands to focus on its main business. It has also made significant external investments, totaling 1.009 billion yuan across seven private equity funds, although these investments have not yet yielded substantial returns [10][11]. - Huaxi Biological has made strategic investments in biotechnology and pharmaceuticals, including a 138 million HKD investment in a Hong Kong-based company, aiming to enhance its platform value in the synthetic biology era [11]. Future Outlook - The company’s ability to recover its core skincare business and convert new investments into actual revenue will be critical for regaining trust in the capital market. The current profit improvements are seen as temporary measures, and without a return to double-digit revenue growth, the company may face further challenges in maintaining profitability [10][12].

Core Insights - Huaxi Biological has officially disclosed a patent for a novel specific sequence PDRN, which demonstrates stability in biological activity, molecular weight, and product quality [1] - The new PDRN technology represents the third generation of products in this field, achieving significant breakthroughs in genomic similarity, raw material stability, and sequence control [1][3] Summary by Sections Patent and Technology Development - The patent (application number: 202511375770.9) for "specific sequence nucleic acid molecules and their application as PDRN" has been publicly disclosed by Huaxi Biological [1] - The new PDRN is based on pure synthetic biotechnology, eliminating reliance on animal extraction and enhancing stability [1][4] Key Innovations - The new PDRN technology achieves 100% similarity in GC content with the human genome, ensuring higher safety and efficacy [3] - The production process does not depend on animal sources, aligning with global regulatory trends and consumer preferences [3][4] - The technology allows for precise control over molecular weight and product quality, enabling traceability and adjustability of active ingredients [3] Efficacy and Safety - The PDRN produced under this new technology significantly enhances the expression of vascular endothelial growth factor (VEGF), promoting the repair of damaged cells more effectively than traditional salmon-extracted PDRN [2][3] - The absence of animal components increases the safety profile of the product, addressing barriers in medical and cosmetic applications [3] Industry Impact - This project marks the first global achievement of a PDRN sequence library with 100% similarity to the human genome, pushing the industry towards precision research and development [4] - The advancements are expected to facilitate the transition from random extraction methods to precise R&D, promoting standardization and high-quality development in the industry [4]

Core Insights - The article highlights the advancements and innovations of Huaxi Biological in the field of extracellular matrix (ECM) science, showcasing its commitment to leading global research and development in anti-aging solutions [1][2][4]. Group 1: ECM Science and Research - Huaxi Biological has established a comprehensive system for ECM science, aligning its research with global life science advancements, and is recognized as a key player in the study of ECM components [2][3]. - The company is actively involved in the research of ECM as a significant aging marker, with international journals acknowledging ECM changes as a major indicator of aging by 2025 [2]. - Huaxi Biological's research integrates a "big omics cross-disciplinary" approach, focusing on the synergistic effects of key ECM substances, transitioning from a "single substance era" to a "system structure era" in anti-aging research [2][3]. Group 2: Innovation and Product Development - The company showcases its ECM research outcomes through innovative products, leveraging China's manufacturing capabilities and a leading pilot transformation platform with 64 pilot production lines [3][4]. - Huaxi Biological has developed a series of products aimed at rebuilding healthy ECM networks and enhancing cellular vitality, with notable achievements in the medical aesthetics sector [3][4]. - The company has received multiple domestic and international awards for its research in key materials like hyaluronic acid, demonstrating its ability to convert cutting-edge research into market-ready products [3][4]. Group 3: Global Expansion and Strategic Partnerships - Huaxi Biological is transitioning from "Chinese manufacturing" to "global standards," establishing a robust intellectual property protection network across over 30 countries and planning to set up a regional center in Europe [4][5]. - As of 2024, international sales of raw materials are projected to account for 49.19% of the company's raw material business revenue, with operations in over 70 countries [4]. - Recent strategic partnerships with companies like LG Household & Health Care and Xcell Therapeutics aim to enhance collaboration in synthetic biology and cell therapy, further solidifying Huaxi Biological's position in the global biopharmaceutical landscape [5][6].

Core Insights - Huaxi Biological Technology Co., Ltd. has achieved a significant breakthrough in the field of bioactive repair components with the public disclosure of a patent for "specific sequence nucleic acid molecules and their application as PDRN" [1] - The new patent introduces a novel specific sequence PDRN (polydeoxyribonucleotide) with stable biological activity, molecular weight, and product quality, marking the third generation of technology in the PDRN field for the company [1] Summary by Sections Patent and Technology Breakthrough - The core achievement of the patent is a new specific sequence PDRN with 100% similarity to the GC content of the human genome, eliminating reliance on animal extraction and ensuring a more stable raw material source [1] - The new technology overcomes traditional animal-derived PDRN limitations, offering controllable sequences and significantly improved purity [1] Applications and Industry Impact - The patent is expected to provide revolutionary solutions for high-end cosmetic repair and medical wound healing sectors, emphasizing three core advantages: controllable sequences, safety, and enhanced efficacy [1] - The previous microbial fermentation-based PDRN production method yielded products with a GC content of 39.5% to 41.5%, closely resembling human GC content at 40% [2] Research and Development Innovations - The company utilized an AI-assisted high-throughput screening approach to identify multiple PDRN sequences from a database of over 60,000 genomic sequences, ensuring high safety and effectiveness in promoting vascular endothelial growth factor (VEGF) expression [2] - The patent also outlines a simple preparation method for specific sequence PDRN, with a fully controllable production process that aligns with sustainable development goals [2] - The establishment of a theoretical and product system linking "sequence and efficacy" will facilitate the industry's transition from random extraction to precise research and development, promoting standardization and high-quality growth in the bioactive component sector [2]

Core Viewpoint - Coty Inc., a century-old French perfume giant, is facing significant challenges, including declining performance across all business segments, plans to divest its mass cosmetics division, and the potential loss of the Gucci brand license, which could severely impact its revenue and profitability [1][28]. Financial Performance - For Q1 of fiscal year 2026, Coty's net revenue was $1.577 billion, a decrease of 6% year-over-year, and an 8% decline on a like-for-like basis [2][9]. - The reported net income was $64.6 million, down 19%, with a net profit margin of 4.1% [2][9]. - The mass beauty segment reported an operating loss of $7.7 million, with a loss rate of 1.5%, and an adjusted operating profit margin of 0.3%, down from 4.3% the previous year [9][28]. Business Segment Analysis - The high-end beauty segment generated $1.07 billion in net revenue, accounting for 68% of total sales, with a reported decline of 4% and a like-for-like decline of 6% [6][9]. - The mass beauty segment's net revenue was $508 million, representing 32% of total sales, with a reported decline of 9% and a like-for-like decline of 11% [6][9]. Regional Performance - All three major regions reported declines, with the Asia-Pacific region experiencing the largest drop of 9%, although there are signs of gradual improvement in the Chinese market [10][12]. - The European, Middle Eastern, and African markets, as the largest revenue source, saw a reported decline of 4% and a like-for-like decline of 9% [21][12]. Competitive Landscape - Coty is losing market share in the competitive global beauty landscape, particularly in the high-end fragrance segment, where it faces intense competition from companies like L'Oréal and Estée Lauder [24][28]. - The potential loss of the Gucci Beauty license, which contributes approximately 8% to Coty's sales and 11% to its profits, poses a significant risk to its future as an independent company [28][30]. Strategic Focus - Coty is focusing on optimizing its remaining high-end beauty operations and exploring new partnerships, while also emphasizing its core strength in the fragrance category [29][30]. - The company has appointed a new president for its mass beauty division, indicating a strategic shift aimed at addressing its current challenges [29].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks in the second half were divided into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with a net profit of CNY 305 million, a decrease of 10.63% [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Performance - The medical aesthetics segment generated CNY 575 million, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [5]. - The epidermal growth factor products saw revenue of CNY 92.38 million, reflecting a growth of 13.73% [5]. Market Position and Valuation - Haohai's current PE (TTM) ratio is 14.82, below the industry average of 20, indicating potential undervaluation [3]. - Despite the stock price decline, the company maintains a net asset value of HKD 26.93 per share, providing an arbitrage opportunity for investors [7]. - Since August 20, 2023, the proportion of shares held by Hong Kong Stock Connect investors has increased from 30.35% to 35.78% [7]. Strategic Focus on Botulinum Toxin - The company has invested USD 31 million in Eirion to develop various botulinum toxin products, aiming to capture a share of the growing market [9]. - The medical aesthetics injection market is dominated by hyaluronic acid and botulinum toxin, which together account for 65% of the market [10]. - The domestic penetration rate for botulinum toxin is significantly lower than in mature markets, suggesting substantial growth potential [12]. Future Outlook - Despite current performance challenges, the company's ongoing development in the botulinum toxin sector may provide a pathway for recovery [14]. - The collaboration with Eirion is expected to yield new products that could enhance market presence and profitability in the future [14].

Group 1 - The company, Huaxi Biological, reported that as of August 20, 2025, the number of shareholders is 32,255 [1]

Group 1 - The medical beauty sector increased by 0.18% on November 6, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] - The trading volume and turnover for *ST Meigu were 137,900 hands and 53.13 million yuan, respectively, with a price increase of 3.95% [1] Group 2 - The medical beauty sector experienced a net outflow of 34.96 million yuan from main funds, while retail investors saw a net inflow of 36.62 million yuan [1] - Individual stock performances included *ST Meigu with a 3.95% increase, Aimeike with a 0.38% increase, Huaxi Biological with a 0.52% decrease, and Jinbo Biological with a 2.54% decrease [1] - The net fund flow for *ST Meigu was -3.52 million yuan, indicating a decrease of 6.63% [2]